WallStSmart

Anheuser Busch Inbev NV ADR (BUD)vsHumana Inc (HUM)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Humana Inc generates 125% more annual revenue ($137.20B vs $60.96B). BUD leads profitability with a 11.9% profit margin vs 0.8%. BUD appears more attractively valued with a PEG of 1.92. BUD earns a higher WallStSmart Score of 63/100 (C+).

BUD

Buy

63

out of 100

Grade: C+

Growth: 6.0Profit: 7.0Value: 4.0Quality: 4.5
Piotroski: 5/9Altman Z: 1.25

HUM

Buy

52

out of 100

Grade: C-

Growth: 6.0Profit: 4.5Value: 5.3Quality: 6.5
Piotroski: 4/9Altman Z: 3.91
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BUDSignificantly Overvalued (-23.3%)

Margin of Safety

-23.3%

Fair Value

$62.65

Current Price

$78.50

$15.85 premium

UndervaluedFair: $62.65Overvalued
HUMUndervalued (+23.7%)

Margin of Safety

+23.7%

Fair Value

$403.67

Current Price

$350.08

$53.59 discount

UndervaluedFair: $403.67Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BUD3 strengths · Avg: 8.3/10
Market CapQuality
$159.17B9/10

Large-cap with strong market position

Operating MarginProfitability
26.7%8/10

Strong operational efficiency at 26.7%

EPS GrowthGrowth
20.3%8/10

Earnings expanding 20.3% YoY

HUM4 strengths · Avg: 8.5/10
Altman Z-ScoreHealth
3.9110/10

Safe zone — low bankruptcy risk

Price/BookValuation
2.3x8/10

Reasonable price relative to book value

Revenue GrowthGrowth
23.5%8/10

Revenue surging 23.5% year-over-year

Free Cash FlowQuality
$1.13B8/10

Generating 1.1B in free cash flow

Areas to Watch

BUD3 concerns · Avg: 3.3/10
PEG RatioValuation
1.924/10

Expensive relative to growth rate

Price/BookValuation
10.5x4/10

Trading at 10.5x book value

Altman Z-ScoreHealth
1.252/10

Distress zone — elevated risk

HUM4 concerns · Avg: 3.3/10
PEG RatioValuation
2.154/10

Expensive relative to growth rate

Return on EquityProfitability
6.1%3/10

ROE of 6.1% — below average capital efficiency

Profit MarginProfitability
0.8%3/10

0.8% margin — thin

Operating MarginProfitability
4.7%3/10

Operating margin of 4.7%

Comparative Analysis Report

WallStSmart Research

Bull Case : BUD

The strongest argument for BUD centers on Market Cap, Operating Margin, EPS Growth. Revenue growth of 12.0% demonstrates continued momentum.

Bull Case : HUM

The strongest argument for HUM centers on Altman Z-Score, Price/Book, Revenue Growth. Revenue growth of 23.5% demonstrates continued momentum.

Bear Case : BUD

The primary concerns for BUD are PEG Ratio, Price/Book, Altman Z-Score.

Bear Case : HUM

The primary concerns for HUM are PEG Ratio, Return on Equity, Profit Margin. A P/E of 40.5x leaves little room for execution misses. Thin 0.8% margins leave little buffer for downturns.

Key Dynamics to Monitor

BUD profiles as a value stock while HUM is a growth play — different risk/reward profiles.

BUD carries more volatility with a beta of 0.79 — expect wider price swings.

HUM is growing revenue faster at 23.5% — sustainability is the question.

Monitor BEVERAGES - BREWERS industry trends, competitive dynamics, and regulatory changes.

Bottom Line

BUD scores higher overall (63/100 vs 52/100) and 12.0% revenue growth. HUM offers better value entry with a 23.7% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Anheuser Busch Inbev NV ADR

CONSUMER DEFENSIVE · BEVERAGES - BREWERS · USA

Anheuser-Busch InBev SA / NV is engaged in the production, distribution and sale of beer, alcoholic beverages and soft drinks worldwide.

Humana Inc

HEALTHCARE · HEALTHCARE PLANS · USA

Humana Inc. is a for-profit American health insurance company based in Louisville, Kentucky.

Visit Website →

Want to dig deeper into these stocks?